Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors Read more about Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Read more about Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor to Present at the 2026 Cantor Global Healthcare Conference Read more about Xencor to Present at the 2026 Cantor Global Healthcare Conference
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter Read more about Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Read more about Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW Read more about Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast Read more about Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
Xencor to Participate at Upcoming Investor Conferences Read more about Xencor to Participate at Upcoming Investor Conferences
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones Read more about Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies Read more about Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
